| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The lancet oncology 17 (9), 1283-1294, 2016 | 1001 | 2016 |
| Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm … P Armand, A Engert, A Younes, M Fanale, A Santoro, PL Zinzani, ... Journal of Clinical Oncology 36 (14), 1428-1439, 2018 | 707 | 2018 |
| Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma MGM Roemer, RA Redd, FZ Cader, CJ Pak, S Abdelrahman, J Ouyang, ... Journal of Clinical Oncology 36 (10), 942-950, 2018 | 323 | 2018 |
| Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death JW Hodge, CT Garnett, B Farsaci, C Palena, KY Tsang, S Ferrone, ... International journal of cancer 133 (3), 624-636, 2013 | 297 | 2013 |
| Effects of conventional therapeutic interventions on the number and function of regulatory T cells M Roselli, V Cereda, MG di Bari, V Formica, A Spila, C Jochems, ... Oncoimmunology 2 (10), e27025, 2013 | 179 | 2013 |
| The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors JW Hodge, A Ardiani, B Farsaci, AR Kwilas, SR Gameiro Seminars in oncology 39 (3), 323-339, 2012 | 166 | 2012 |
| A phase 1 study of nivolumab in combination with ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039) S Ansell, ME Gutierrez, MA Shipp, D Gladstone, A Moskowitz, I Borello, ... Blood 128 (22), 183, 2016 | 153 | 2016 |
| Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy B Farsaci, JP Higgins, JW Hodge International journal of cancer 130 (8), 1948-1959, 2012 | 147 | 2012 |
| Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer JL Gulley, RA Madan, KY Tsang, C Jochems, JL Marté, B Farsaci, ... Cancer immunology research 2 (2), 133-141, 2014 | 143 | 2014 |
| Therapeutic cancer vaccines J Schlom, JW Hodge, C Palena, KY Tsang, C Jochems, JW Greiner, ... Advances in cancer research 121, 67-124, 2014 | 93 | 2014 |
| Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model A Ardiani, B Farsaci, CJ Rogers, A Protter, Z Guo, TH King, D Apelian, ... Clinical Cancer Research 19 (22), 6205-6218, 2013 | 90 | 2013 |
| Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial CR Heery, NK Ibrahim, PM Arlen, M Mohebtash, JL Murray, K Koenig, ... JAMA oncology 1 (8), 1087-1095, 2015 | 89 | 2015 |
| Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines B Farsaci, RN Donahue, MA Coplin, I Grenga, LM Lepone, AA Molinolo, ... Cancer immunology research 2 (11), 1090-1102, 2014 | 78 | 2014 |
| Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age G Milone, S Mercurio, A Strano, S Leotta, V Pinto, K Battiato, S Coppoletta, ... Cytotherapy 9 (4), 348-355, 2007 | 62 | 2007 |
| Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy PS Kim, C Jochems, I Grenga, RN Donahue, KY Tsang, JL Gulley, ... The Journal of Immunology 192 (6), 2622-2633, 2014 | 53 | 2014 |
| Effect of a small molecule BCL‐2 inhibitor on immune function and use with a recombinant vaccine B Farsaci, H Sabzevari, JP Higgins, MG Di Bari, S Takai, J Schlom, ... International journal of cancer 127 (7), 1603-1613, 2010 | 51 | 2010 |
| TGF-β modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression MG Di Bari, MEC Lutsiak, S Takai, S Mostböck, B Farsaci, ... Cancer immunology, immunotherapy 58, 1809-1818, 2009 | 41 | 2009 |
| Analyses of pretherapy peripheral immunoscore and response to vaccine therapy B Farsaci, RN Donahue, I Grenga, LM Lepone, PS Kim, B Dempsey, ... Cancer immunology research 4 (9), 755-765, 2016 | 32 | 2016 |
| PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment I Grenga, RN Donahue, L Lepone, J Bame, J Schlom, B Farsaci Journal for immunotherapy of cancer 2 (Suppl 3), 2014 | 28 | 2014 |
| Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study. A Younes, A Santoro, PL Zinzani, J Timmerman, SM Ansell, P Armand, ... Journal of Clinical Oncology 34 (15_suppl), 7535-7535, 2016 | 27 | 2016 |
James W. HodgeNational Cancer Institute, NIH在 mail.nih.gov 的电子邮件经过验证
